Research
Hormonal
Weightlessness and reduced mechanical loading (e.g., spaceflight, bed rest) cause rapid, site-specific bone loss, particularly in weight-bearing bones, with recovery being significantly slower than the rate of loss.
Prolonged periods of reduced weight-bearing activity, such as bed rest or sedentary living, lead to rapid bone loss, especially in the hips and spine. Recovery of bone density is slow and incomplete. Regular weight-bearing exercise is essential to counteract these effects.
StrongSupportsVERY_HIGH confidence
Astronauts typically lose bone during exposure to weightlessness... Bone mineral density (BMD) in crewmembers aboard the International Space Station (ISS) showed precipitous declines at weight-bearing sites... The rate of recovery of BMD following restoration of normal weight bearing is much slower than the rate of loss.
Why this rating
Based on consistent findings from spaceflight, bed rest, and animal models.
Source
Influence of body weight on bone mass, architecture and turnover
Urszula T. Iwaniec et al. · Journal of Endocrinology · 2016
DOI 10.1530/joe-16-0089
narrative_reviewCited 187×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Increased body weight and mechanical loading via the mechanostat increase bone mass and reduce osteoporosis prevalence, but this benefit plateaus or reverses at morbid obesity levels due to compromised bone quality and altered fracture mechanics.Good
- Leptin and estrogen signaling modulate the skeleton's sensitivity to mechanical loading, with leptin deficiency requiring higher body weight to achieve equivalent bone mass.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →